DL
Therapeutic Areas
Scilex Holding Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZTlido® (lidocaine topical system) 1.8% | Post-herpetic neuralgia (PHN) | Approved |
| SP-102 (SEMDEXA™) | Lumbar radicular pain (sciatica) | Phase 3 |
| SP-103 (STRACUVA™) | Acute low back pain | Phase 2 |
| SP-104 (low-dose naltrexone) | Fibromyalgia | Phase 2 |
| GLOPERBA® (colchicine USP) | Gout flare prophylaxis | Approved |
Leadership Team at Scilex Holding
JS
Jaisim Shah
Chief Executive Officer and President
EC
Elizabeth Czerepak
Chief Financial Officer
JG
Jeffrey Gudin, M.D.
Chief Medical Officer
SM
Stephen Ma
Chief Operating Officer and General Counsel
HJ
Henry Ji, Ph.D.
Chairman of the Board of Directors